Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) have earned an average rating of “Moderate Buy” from the eleven research firms that are covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $26.8571.

A number of analysts recently issued reports on the company. Guggenheim dropped their price objective on Zevra Therapeutics from $29.00 to $24.00 and set a “buy” rating on the stock in a report on Monday. HC Wainwright reaffirmed a “buy” rating and set a $26.00 target price on shares of Zevra Therapeutics in a report on Tuesday, June 23rd. BTIG Research decreased their price target on Zevra Therapeutics from $27.00 to $24.00 and set a “buy” rating on the stock in a research report on Monday. Cantor Fitzgerald increased their price target on shares of Zevra Therapeutics from $24.00 to $34.00 and gave the stock an “overweight” rating in a report on Monday, June 8th. Finally, Wall Street Zen upgraded shares of Zevra Therapeutics from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th.

Institutional Trading of Zevra Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Zevra Therapeutics by 6.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,761 shares of the company’s stock valued at $238,000 after purchasing an additional 1,812 shares in the last quarter. Strs Ohio purchased a new stake in shares of Zevra Therapeutics in the first quarter worth $125,000. Creative Planning purchased a new stake in shares of Zevra Therapeutics in the second quarter worth $92,000. Rhumbline Advisers raised its position in shares of Zevra Therapeutics by 11.6% in the second quarter. Rhumbline Advisers now owns 83,221 shares of the company’s stock worth $733,000 after buying an additional 8,636 shares in the last quarter. Finally, Quantbot Technologies LP bought a new stake in Zevra Therapeutics during the second quarter valued at $255,000. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

Zevra Therapeutics Price Performance

Shares of ZVRA opened at $9.78 on Friday. The company has a market cap of $578.19 million, a PE ratio of 4.91 and a beta of 0.85. The stock has a 50-day moving average of $12.34 and a 200-day moving average of $10.50. Zevra Therapeutics has a one year low of $7.16 and a one year high of $15.03.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.18 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.12. Zevra Therapeutics had a net margin of 101.58% and a return on equity of 51.49%. The firm had revenue of $36.22 million for the quarter, compared to the consensus estimate of $31.96 million. Analysts expect that Zevra Therapeutics will post 0.56 EPS for the current fiscal year.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.